INFR yields 2.49% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, INFR + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of INFR + JNJ for your $10,000?
INFR invests in equity securities from the infrastructure industry that meet sustainability and financial criteria. Infrastructure companies considered could be of any size with attractive valuations, distributions, and cash flow characteristics, stretching across multiple sub-industries, including oil and gas storage/transportation, gas utilities, and airport services (excluding air navigation service providers). The proprietary methodology applies inclusionary liquidity, exposure, quality, and income screens that evaluates ownership of physical assets, nature of services, monopoly characteristics, and contractual and/or regulatory rights. Qualified companies are assigned a rating across a five-year horizon that assesses their ESG focus, integration, and efforts, specifically climate-related risks and opportunities. The fund may invest up to 20% of its assets in non-US companies. As an actively managed fund, the portfolio managers have full discretion with investments.
Full INFR Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.